Twist Bioscience Corp’s recent filing unveils that its Chief Financial Officer Laponis Adam unloaded Company’s shares for reported $93450.0 on Oct 08 ’25. In the deal valued at $31.15 per share,3,000 shares were sold. As a result of this transaction, Laponis Adam now holds 94,042 shares worth roughly $2.87 million.
Then, Laponis Adam sold 2,517 shares, generating $82,865 in total proceeds. Upon selling the shares at $32.92, the Chief Financial Officer now owns 91,525 shares.
Before that, Laponis Adam bought 2,517 shares. Twist Bioscience Corp shares valued at $82,864 were divested by the Officer at a price of $32.92 per share.
Wolfe Research initiated its Twist Bioscience Corp [TWST] rating to an Outperform in a research note published on December 13, 2024; the price target was $60. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in early June with a ‘”a Buy”‘ rating. Goldman also remained covering TWST and has increased its forecast on January 17, 2024 with a “Buy” recommendation from previously “Neutral” rating. Berenberg started covering the stock on September 27, 2023. It rated TWST as “a Buy”.
Price Performance Review of TWST
On Tuesday, Twist Bioscience Corp [NASDAQ:TWST] saw its stock jump 1.36% to $30.55. Over the last five days, the stock has lost -1.83%. Twist Bioscience Corp shares have fallen nearly -26.65% since the year began. Nevertheless, the stocks have fallen -34.26% over the past one year.
How much short interest is there in Twist Bioscience Corp?
A steep rise in short interest was recorded in Twist Bioscience Corp stocks on 2025-09-30, growing by 2.75 million shares to a total of 12.98 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 10.23 million shares. There was a rise of 21.17%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 05, 2023 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating along with a $33 price target.
